Novartis COVID-19 Therapy Could Overcome Escape Variant Problem
Protein Therapeutic Enters Pivotal Trial
The DARPin candidate will not gain emergency approval before early 2022, but its likely ability to sustain efficacy regardless of SARS-CoV-2 mutations could be valuable as new variants emerge.
